- ￥137 - 1824
- TargetMol
- T4089
- 2026年07月07日
2 年钻石会员
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
相关阅读
香烟烟雾如何加速声带纤维化？CD44-透明质酸轴是关键通路Takara 秋促来袭，提取+反转录+定量套装仅 1200 元abinScience 体内级抗体 全年锁价 低至 ￥1200阿拉丁 22万+ 科研级产品现货速发，品质严控、科研无忧- 详细信息
- 文献和实验
- 技术资料
- CAS号：
1426138-42-2
- 规格：
1mLx10mM(inDMSO)/1mg/5mg/10mg/25mg/50mg/100mg
| 规格： | 1mLx10mM(inDMSO) | 产品价格： | ￥322.0 |
|---|---|---|---|
| 规格： | 1mg | 产品价格： | ￥137.0 |
| 规格： | 5mg | 产品价格： | ￥313.0 |
| 规格： | 10mg | 产品价格： | ￥436.0 |
| 规格： | 25mg | 产品价格： | ￥856.0 |
| 规格： | 50mg | 产品价格： | ￥1256.0 |
| 规格： | 100mg | 产品价格： | ￥1824.0 |
Product Introduction
Bioactivity
| 名称 | FX1 |
| 描述 | FX1 is an effective and selective BCL6 inhibitor (IC50: 35 μM). |
| 细胞实验 | Cell viability is determined with the fluorescent redox dye. Fluorescence is determined for 3 replicates per treatment condition or vehicle with the microplate reader. The drug effect as 100-percentage viability is calculated. Through dose-effect curves the drug concentration that inhibits the growth of cell lines by 50% compared with vehicle (GI50) is determined. Experiments are performed in triplicate. For combination treatments, cells are exposed to a dose curve of each drug alone or their combination in a constant ratio, and cell viability is determined. To compare different schedules of treatments, the cells are treated in triplicate as follows: FX1 and doxorubicin simultaneously and cells treated for 48 hours; FX1 first and 24 hours after doxorubicin is added and treats for an extra 48 hours; doxorubicin first and 24 hours after FX1 is added and treats for an extra 48 hours. Then, the software is used to plot dose-effect curves and calculate the dose-reduction index [1]. |
| 动物实验 | Cell viability is determined with the fluorescent redox dye. Fluorescence is determined for 3 replicates per treatment condition or vehicle with the microplate reader. Cell viability of the drug-treated cells is normalized to their vehicle-treated controls, and the results are expressed as percentage viability. The drug effect as 100-percentage viability is calculated. Through dose-effect curves the drug concentration that inhibits the growth of cell lines by 50% compare with vehicle (GI50) is determined. Experiments are performed in triplicate. For combination treatments, cells are exposed to a dose curve of each drug alone or their combination in constant ratio, and cell viability is determined. To compare different schedules of treatments, the cells are treated in triplicate as follows: FX1 and doxorubicin simultaneously and cells treated for 48 hours; FX1 first and 24 hours after doxorubicin is added and treats for an extra 48 hours; doxorubicin first and 24 hours after FX1 is added and treats for an extra 48 hours. Then, the software is used to plot dose-effect curves and calculate the dose-reduction index[1]. |
| 体外活性 | FX1显著降低了SMRT和BCOR对所有三个BCL6靶基因的招募。在BCL6阴性的DLBCL细胞系中，这些位点几乎不含SMRT，且不受FX1影响。经过50 μM FX1处理6小时后，与79-6相比，FX1在定量ChIP试验中打破BCL6与SMRT结合的优越性在DLBCL细胞的头对头比较中变得明显。 |
| 体内活性 | FX1对总B细胞的丰度没有影响。FX1显著消耗生发中心B细胞（GL7+FAS+B220+）。用B220抗体染色揭示了正常的B细胞滤泡结构，而针对生发中心B细胞特异性标记的花生凝集素染色显示GCs的显著丧失。半衰期估计为大约12小时。与对照组相比，用FX1处理的小鼠固定器官的脾脏、肺、胃肠道、肾、心脏、肝脏和骨髓的H&E染色切片未见毒性、炎症或感染迹象。 |
| 存储条件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| 溶解度 | DMSO : 25 mg/mL (67.78 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 1 mg/mL (2.71 mM), Sonication is recommended. |
| 关键字 | Inhibitor | inhibit | FX-1 | FX1 | FX 1 | BCL-6 | Bcl-2 Family | Apoptosis |
| 相关产品 | Formamide | Urea | Sodium Molybdate | Dimethyl phthalate | Aceglutamide | Alginic acid | Cysteamine hydrochloride | Metronidazole | Sildenafil citrate | Citric Acid Triammonium | Stavudine | Tamoxifen |
| 相关库 | Inhibitor Library | Bioactive Compound Library | Anti-Cancer Compound Library | Bioactive Compounds Library Max | Mitochondria-Targeted Compound Library | Apoptosis Compound Library | Anti-Aging Compound Library | Highly Selective Inhibitor Library | Hematonosis Compound Library | Immunology/Inflammation Compound Library | PPI Inhibitor Library | Target-Focused Phenotypic Screening Library |
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验该产品被引用文献
官网有文献
相关实验
网络 第十九章 杂环化合物和生物碱 杂环化合物在自然界分布很广，其数量几乎占已知有机化合物的三分之一，用途也很多。许多重要的物质如叶绿素、血红素、核酸以及临床应用的一些有显著疗效的天然药物和合成药物等，都含有杂环化合物的结构。生物碱多是中草药的有效成分，绝大多数是含氮的杂环化合物。本章内容与医学关系密切，具有重要意义。
分子中具有高能键的化合物。在生物体内主要有上式（Ⅰ）和（Ⅱ）两种结构的高能化合物。其作用为贮藏能量（例如 ATP、肌酸磷酸）和作为产生 ATP源的中间代谢产物（例如磷酸烯醇丙酮酸）以及合成反应的中间物质（例如酰基辅酶 A），在蛋白质的结构（ conformation）变化周期的第一阶段上（例如钠钾 ATP酶的羧基磷酸中间体）也具有重要作用。多数高等化合物具有磷酸基，但也有例外。
由不同种元素组成的纯净物叫做化合物。化合物一般有固定的组成。化合物的组成一般可用化学式表示。化合物具有确定的物理性质和化学性质，不同于其组成元素的性质。化合物中的元素不能用简单的机械方法或物理方法分开，而必须用化学方法才能分离。
技术资料暂无技术资料 索取技术资料
文献支持
化合物 FX1【1426138-42-2】
￥137 - 1824
